Vertex Pharma downgraded by Wolfe Research
$VRTX
Biotechnology: Pharmaceutical Preparations
Health Care
Wolfe Research downgraded Vertex Pharma from Outperform to Peer Perform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/6/2025 | $460.00 | Equal Weight → Overweight | Wells Fargo |
| 5/7/2025 | Outperform → Peer Perform | Wolfe Research | |
| 5/6/2025 | $503.00 | Outperform → Market Perform | Leerink Partners |
| 4/22/2025 | $535.00 | Overweight | Cantor Fitzgerald |
| 2/12/2025 | $408.00 → $424.00 | Sell → Hold | Canaccord Genuity |
| 2/11/2025 | Sell → Hold | Canaccord Genuity | |
| 1/30/2025 | $460.00 | Overweight → Equal Weight | Wells Fargo |
| 12/20/2024 | $600.00 → $535.00 | Buy | H.C. Wainwright |
Wells Fargo upgraded Vertex Pharma from Equal Weight to Overweight and set a new price target of $460.00
Wolfe Research downgraded Vertex Pharma from Outperform to Peer Perform
Leerink Partners downgraded Vertex Pharma from Outperform to Market Perform and set a new price target of $503.00
For Immediate Release: January 30, 2025 Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals reach the brain. Journavx is the first dr
For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali
Submission status for VERTEX PHARMS INC's drug TRIKAFTA (COPACKAGED) (SUPPL-11) with active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 212273, Application Classification: Labeling
10-Q - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)
8-K - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)
144 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
— Total revenue of $2.96 billion, a 12% increase compared to Q2 2024; reiterated full year 2025 financial guidance, including revenue guidance of $11.85 to $12 billion — — Continued strong execution of CASGEVY®, ALYFTREK® and JOURNAVX® launches — — Rapid advancement of next wave of clinical programs through pivotal development, with suzetrigine in DPN, zimislecel in T1D, povetacicept in IgAN and pMN, and inaxaplin in AMKD — — David Altshuler, M.D., PhD., Chief Scientific Officer (CSO), announces intent to retire August 1, 2026; as part of planned transition, Mark Bunnage, D.Phil., SVP of Global Research, to assume role of CSO effective February 1, 2026 — Vertex Pharmaceuticals Incor
– Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint – – Treatment with VX-993 was generally safe and well tolerated, with safety profile similar to placebo arm – Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ranging study evaluating the safety and efficacy of its investigational selective NaV1.8 pain signal inhibitor, VX-993, in treating acute pain after bunionectomy surgery. Treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint of the time-w
KBRA announces the assignment of preliminary ratings to five classes of VRTX 2025-HQ, a CMBS single-borrower securitization. The collateral for the transaction is a $600 million portion of a $1.0 billion fixed rate, interest-only first lien mortgage loan. The fixed-rate loan has a five-year term and requires monthly interest-only payments based on an assumed interest rate of 6.25%. The loan is secured by the borrower's fee simple interest in Vertex HQ , two 15-story, Class-A, LEED Gold office tower containing 1.1 million sf. The building is located in the Seaport neighborhood of downtown Boston. The buildings were developed in 2013 as a built-to-suit corporate headquarters for Vertex Pharma
— Total revenue of $2.96 billion, a 12% increase compared to Q2 2024; reiterated full year 2025 financial guidance, including revenue guidance of $11.85 to $12 billion — — Continued strong execution of CASGEVY®, ALYFTREK® and JOURNAVX® launches — — Rapid advancement of next wave of clinical programs through pivotal development, with suzetrigine in DPN, zimislecel in T1D, povetacicept in IgAN and pMN, and inaxaplin in AMKD — — David Altshuler, M.D., PhD., Chief Scientific Officer (CSO), announces intent to retire August 1, 2026; as part of planned transition, Mark Bunnage, D.Phil., SVP of Global Research, to assume role of CSO effective February 1, 2026 — Vertex Pharmaceuticals Incor
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its second quarter 2025 financial results on Monday, August 4, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Second Quarter 2025 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived we
— Total revenue of $2.77 billion, a 3% increase compared to Q1 2024; raised the low end of total revenue guidance by $100 million to a new range of $11.85 to $12 billion — — Strong progress with CASGEVY®, ALYFTREK™ and JOURNAVX™ launches — — Povetacicept (pove) IgAN Phase 3 interim analysis (IA) cohort fully enrolled and zimislecel Phase 3 program to complete dosing this quarter, setting up potential filings in 2026; inaxaplin Phase 3 IA cohort on track to complete enrollment in the second half of 2025 — — Four programs already in pivotal development, with pivotal study of pove in primary membranous nephropathy (pMN) to start this year — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Nancy Thornberry has been appointed to its Board of Directors as an independent director. Ms. Thornberry has more than 35 years of experience in the pharmaceutical and biotech industries, spanning drug discovery, development and commercialization. She founded and served as Chief Executive Officer of Kallyope until 2021 and remains on its Board of Directors and is Chair of Research & Development. Prior to joining Kallyope, Ms. Thornberry spent more than 30 years at Merck & Co., Inc., most recently as Senior Vice President and Global Franchise Head, Diabetes and Endocrinology, with responsibility for discovery and clinical
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Michel Lagarde has been appointed to its Board of Directors as an independent director. Mr. Lagarde is a senior health care and business leader with global expertise, currently serving as Chief Operating Officer and Executive Vice President of Thermo Fisher Scientific Inc. Prior to Thermo Fisher, Mr. Lagarde served as President and Chief Operating Officer of Patheon, a contract manufacturer to the biopharma industry, and as a Managing Director at JLL Partners, a private equity firm investing in health care services. "We are delighted to have Michel join the Vertex Board. His deep experience across numerous segments of
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that E. Morrey Atkinson, Ph.D., has been appointed Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations, effective immediately. Dr. Atkinson has served as Senior Vice President of Global Commercial Manufacturing and Supply Chain since July 2020. This new role and function unifies responsibility for small molecule, cell and gene therapies across preclinical, clinical and commercial biopharmaceutical sciences, manufacturing operations and global supply chain. "Over the last three years, Morrey has played a vital role in building out our commercial manufa